Osimertinib Price in India: — Brand, Generic and Monthly Cost

It depends on your specific policy. Many group health insurance plans and some individual plans include cancer drug riders that cover targeted therapies. Ask your insurer directly and in writing, naming osimertinib, and ask what documentation is needed — typically an oncologist's letter and the prescription. Some insurers require pre-authorisation before the first purchase. If your plan currently excludes the drug, ask whether a top-up or cancer-specific rider is available for future cycles.

AstraZeneca runs a programme in India for patients who cannot afford Tagrisso at the retail price. Eligibility is generally income-linked and the terms change periodically. The application is typically initiated through your treating oncologist or the hospital social worker, not directly by the patient. Ask your team whether the programme is currently open and what the income threshold is. Do not assume you are ineligible without asking — many families who qualify never apply because they assumed it was not for them.

The active molecule is identical. CDSCO requires approved generics to demonstrate bioequivalence — meaning the drug is absorbed into the body at the same rate and to the same extent as the original. The clinical question your oncologist may have is whether to change product if you are currently responding well on a particular version. That is a medical judgement, not a cost judgement, and your treating team should make it with you rather than you switching independently.

PM-JAY covers certain cancer treatments within its package rates, but coverage of specific targeted therapies varies by state and by the empanelled hospital. Ask the hospital's Ayushman Bharat desk specifically about osimertinib before assuming it is included. If the branded version is not covered under your package, ask whether the generic falls within a different package ceiling — the cost difference is large enough to matter for scheme limits.

Yes. Osimertinib is available as both 80mg and 40mg tablets, and the cost per pack is different for each strength. Your oncologist prescribes the dose appropriate for your treatment — either as the standard dose or as a reduced dose if you have experienced side effects. Do not reduce your dose independently to save money. If the cost of your prescribed dose is a problem, say so directly to your treating team — that is the right conversation to have, not a self-adjustment.

Tell your oncologist directly. This is not an unusual conversation in a cancer clinic and your team should know what options exist for your situation. These may include the manufacturer programme, state government drug supply schemes, NGO-linked access programmes, or a review of whether a different treatment approach is appropriate. Saying nothing means you may reduce or stop treatment without your team knowing — which is the outcome everyone is trying to avoid. The cost conversation belongs in the clinic, not after.